Current status of Cancer Nanotheranostics: Emerging strategies for cancer management.
cancer
nanoparticles
photodynamic therapy
photosensitive agents
photothermal therapy
theranostics
Journal
Nanotheranostics
ISSN: 2206-7418
Titre abrégé: Nanotheranostics
Pays: Australia
ID NLM: 101698994
Informations de publication
Date de publication:
2023
2023
Historique:
received:
30
12
2022
accepted:
20
03
2023
medline:
9
5
2023
pubmed:
8
5
2023
entrez:
8
5
2023
Statut:
epublish
Résumé
Cancer diagnosis and management have been a slow-evolving area in medical science. Conventional therapies have by far proved to have various limitations. Also, the concept of immunotherapy which was thought to revolutionize the management of cancer has presented its range of drawbacks. To overcome these limitations nanoparticulate-derived diagnostic and therapeutic strategies are emerging. These nanomaterials are to be explored as they serve as a prospect for cancer theranostics. Nanoparticles have a significant yet unclear role in screening as well as therapy of cancer. However, nanogels and Photodynamic therapy is one such approach to be developed in cancer theranostics. Photoactive cancer theranostics is a vivid area that might prove to help manage cancer. Also, the utilization of the quantum dots as a diagnostic tool and to selectively kill cancer cells, especially in CNS tumors. Additionally, the redox-sensitive micelles targeting the tumor microenvironment of the cancer are also an important theranostic tool. This review focuses on exploring various agents that are currently being studied or can further be studied as cancer theranostics.
Identifiants
pubmed: 37151802
doi: 10.7150/ntno.82263
pii: ntnov07p0368
pmc: PMC10161386
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
368-379Informations de copyright
© The author(s).
Déclaration de conflit d'intérêts
Competing Interests: The authors have declared that no competing interest exists.
Références
Chem Soc Rev. 2019 Apr 1;48(7):2053-2108
pubmed: 30259015
Vaccines (Basel). 2022 Dec 15;10(12):
pubmed: 36560560
ACS Nano. 2015 Sep 22;9(9):9199-209
pubmed: 26308265
ACS Nano. 2017 Mar 28;11(3):2313-2381
pubmed: 28290206
Anticancer Agents Med Chem. 2020;20(11):1288-1299
pubmed: 31429694
Small. 2021 Nov;17(44):e2102646
pubmed: 34382346
Molecules. 2023 Mar 13;28(6):
pubmed: 36985578
Biomaterials. 2011 Aug;32(22):5252-61
pubmed: 21513975
Biomaterials. 2012 May;33(15):3980-9
pubmed: 22364699
Coord Chem Rev. 2019 Jan 15;379:99-120
pubmed: 30559508
Am J Obstet Gynecol. 2015 Jan;212(1):9-17
pubmed: 24959654
Radiology. 2009 Feb;250(2):398-406
pubmed: 19188313
J BioX Res. 2019 Dec;2(4):159-168
pubmed: 33088609
Nanomedicine (Lond). 2010 Apr;5(3):347-60
pubmed: 20394529
Nature. 2013 Sep 19;501(7467):346-54
pubmed: 24048067
Acta Biomater. 2013 Jul;9(7):7410-9
pubmed: 23535235
Nanomedicine (Lond). 2015 Jan;10(1):1-3
pubmed: 25597770
Nano Lett. 2011 Jul 13;11(7):2678-83
pubmed: 21644516
Nanotheranostics. 2017;1(1):1-22
pubmed: 28191450
Cancer Res. 2010 Mar 15;70(6):2180-90
pubmed: 20215497
J Control Release. 2016 Mar 28;226:77-87
pubmed: 26860283
Theranostics. 2016 Jun 15;6(9):1362-77
pubmed: 27375785
Theranostics. 2012;2(11):1040-53
pubmed: 23227121
J Nanobiotechnology. 2018 Sep 19;16(1):71
pubmed: 30231877
Front Oncol. 2022 Mar 29;12:867655
pubmed: 35425710
Biomaterials. 2014 Jan;35(4):1249-56
pubmed: 24211079
Nucl Med Mol Imaging. 2020 Apr;54(2):65-80
pubmed: 32377258
ACS Nano. 2015 Jan 27;9(1):134-45
pubmed: 25559896
Sci Rep. 2015 Oct 06;5:14759
pubmed: 26440059
J Control Release. 2008 Dec 18;132(3):193-9
pubmed: 18687371
Biomaterials. 2012 Apr;33(12):3494-501
pubmed: 22306020
Nanotheranostics. 2023 Feb 5;7(2):202-209
pubmed: 36793352
Cancers (Basel). 2020 Sep 29;12(10):
pubmed: 33003374
Asian J Pharm Sci. 2021 Jan;16(1):24-46
pubmed: 33613728
Front Bioeng Biotechnol. 2019 Aug 14;7:197
pubmed: 31475143
Nanotheranostics. 2017 Jan 1;1(1):38-58
pubmed: 29071178
Curr Drug Targets. 2015;16(6):528-41
pubmed: 25901526
Nanomaterials (Basel). 2020 Aug 29;10(9):
pubmed: 32872399
Cancers (Basel). 2023 Feb 06;15(4):
pubmed: 36831369
Crit Rev Oncol Hematol. 2002 Jul;43(1):33-56
pubmed: 12098606
Biomaterials. 2011 Apr;32(11):2969-78
pubmed: 21257200
Contemp Oncol (Pozn). 2021;25(1):45-52
pubmed: 33911981
Theranostics. 2012;2(7):714-22
pubmed: 22896773
Nat Rev Mater. 2017;2:
pubmed: 29075517
Angew Chem Int Ed Engl. 2008;47(29):5362-5
pubmed: 18551493
Biomaterials. 2012 Apr;33(11):3071-82
pubmed: 22281424
J Drug Target. 2007 Nov;15(9):553-84
pubmed: 17968711
Expert Opin Drug Deliv. 2013 Apr;10(4):529-43
pubmed: 23316695
Expert Rev Gastroenterol Hepatol. 2017 Sep;11(9):821-834
pubmed: 28650209
Biochem J. 2016 Feb 15;473(4):347-64
pubmed: 26862179
IET Nanobiotechnol. 2021 May;15(3):247-256
pubmed: 34694670
Indian J Med Res. 2022 Oct-Nov;156(4&5):598-607
pubmed: 36510887
Sci Rep. 2014 Nov 17;4:7072
pubmed: 25400232
Nanomedicine (Lond). 2009 Jan;4(1):105-18
pubmed: 19093899
Phys Med Biol. 1999 Mar;44(3):R23-56
pubmed: 10211798
Nat Med. 2007 Mar;13(3):372-7
pubmed: 17322898
Nanomedicine (Lond). 2022 Apr;17(8):547-568
pubmed: 35259920
Bioimpacts. 2014;4(2):55-67
pubmed: 25035848
Chem Rev. 2021 Feb 10;121(3):1746-1803
pubmed: 33445874
Adv Healthc Mater. 2013 Apr;2(4):576-84
pubmed: 23184673
J Ther Ultrasound. 2013 Jul 01;1:11
pubmed: 25516800
Biomaterials. 2014 Feb;35(6):1932-43
pubmed: 24315578
J Control Release. 2008 Sep 10;130(2):107-14
pubmed: 18582982
Vaccines (Basel). 2022 Dec 04;10(12):
pubmed: 36560482
Anal Chem. 2018 Feb 6;90(3):2170-2177
pubmed: 29336550
Biotechnol J. 2011 Nov;6(11):1342-7
pubmed: 22069094
Acta Biomater. 2017 Jun;55:466-480
pubmed: 28373086
Adv Colloid Interface Sci. 2014 Jul;209:8-39
pubmed: 24491963
Int J Nanomedicine. 2012;7:1599-611
pubmed: 22619515
J Control Release. 2016 May 10;229:183-191
pubmed: 27016140
Nanotheranostics. 2023 Jan 9;7(2):128-141
pubmed: 36793354
Nat Med. 2015 Aug;21(8):846-53
pubmed: 26248267
J Pers Med. 2021 Aug 06;11(8):
pubmed: 34442415
Curr Oncol Rep. 2007 Mar;9(2):109-14
pubmed: 17288875
Int J Pharm. 2021 May 1;600:120485
pubmed: 33744447
Sci Rep. 2020 Jun 17;10(1):9765
pubmed: 32555349
NMR Biomed. 2013 Aug;26(8):1042-9
pubmed: 23832526
Nanotechnology. 2013 Aug 16;24(32):325101
pubmed: 23867977
Cancers (Basel). 2023 Jan 16;15(2):
pubmed: 36672492
Expert Opin Drug Deliv. 2021 Feb;18(2):205-227
pubmed: 32969740
Proc Natl Acad Sci U S A. 2007 Sep 25;104(39):15549-54
pubmed: 17875985
Mol Pharm. 2013 Oct 7;10(10):3946-58
pubmed: 24020847
ACS Nano. 2010 Jul 27;4(7):3689-96
pubmed: 20550178
J Mater Chem B. 2013 Mar 14;1(10):1482-1490
pubmed: 23589767
Adv Drug Deliv Rev. 2017 Apr;113:61-86
pubmed: 27266447
Nat Commun. 2016 Oct 21;7:13193
pubmed: 27767031
ACS Nano. 2013 Jun 25;7(6):5320-9
pubmed: 23721576
J Res Med Sci. 2019 Apr 26;24:38
pubmed: 31143239
Clin Cancer Res. 1999 Jan;5(1):83-94
pubmed: 9918206
Theranostics. 2016 Apr 27;6(7):948-68
pubmed: 27217830
Theranostics. 2012;2(10):1020-36
pubmed: 23139729
Ann Oncol. 2010 Feb;21(2):382-388
pubmed: 19633055
Sci Transl Med. 2015 Nov 18;7(314):314ra183
pubmed: 26582898
Theranostics. 2013 Apr 23;3(6):366-76
pubmed: 23781284
Biomedicines. 2023 Jan 18;11(2):
pubmed: 36830794
Nanoscale. 2014 Aug 21;6(16):9494-530
pubmed: 25030381
Mol Cancer. 2021 Feb 25;20(1):41
pubmed: 33632261
Int J Nanomedicine. 2015 Mar 24;10:2347-62
pubmed: 25848255
Clin Invest Med. 2008;31(3):E160-7
pubmed: 18544279
Nat Rev Drug Discov. 2005 Feb;4(2):145-60
pubmed: 15688077